Trials / Completed
CompletedNCT05179356
Dapagliflozin in Pulmonary Arterial Hypertension
Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Mads Ersbøll · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension
Detailed description
The objective of this study is to evaluate the effects of oral dapagliflozin (Forxiga®) treatment versus placebo in clinically stable patients with pulmonary arterial hypertension or CTEPH on background vasodilator combination therapy on cardio-pulmonary exercise capacity, pulmonary vascular hemodynamics, RV function and metabolomic profile of the pulmonary vascular endothelium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin 10 MG [Farxiga] | Dapagliflozin 10 mg given once daily for three months |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2026-01-13
- Completion
- 2026-01-13
- First posted
- 2022-01-05
- Last updated
- 2026-01-21
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05179356. Inclusion in this directory is not an endorsement.